- Home
- INM
INM
InMed Pharmaceuticals Inc.
as 11-14-2024 4:00pm EST
| Founded: | 1981 | Country: | Canada |
| Employees: | N/A | City: | VANCOUVER |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.12 - $5.41 | Next Earning Date: | 11-22-2024 |
| Revenue: | $4,597,730 | Revenue Growth: | 11.18% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest InMed Pharmaceuticals Inc. News
INM Breaking Stock News: Dive into INM Ticker-Specific Updates for Smart Investing
Newsfile
6 days ago
InMed Announces Share Consolidation to Satisfy Nasdaq Listing Rules
Newsfile
10 days ago
InMed Pharmaceuticals Announces Decision by NASDAQ Hearings Panel to Grant Exception to Implement Share Consolidation to Satisfy NASDAQ Listing Rules
Newsfile
18 days ago
InMed Pharmaceuticals Files Additional Patent Application for INM-901 in the Treatment of Neurodegenerative Conditions Including Alzheimer's Disease
Newsfile
22 days ago
InMed to Participate in Fierce Biotech Webinar on Neuroinflammation in Alzheimer's Disease
Newsfile
24 days ago
InMed Appoints Dr. Barry Greenberg, Johns Hopkins University School of Medicine, to its Scientific Advisory Board
Newsfile
2 months ago
InMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update
Newsfile
2 months ago
InMed Receives NASDAQ Delisting Notice, and Confirms it has Filed an Appeal and Obtained a Panel Hearing Date
Newsfile
3 months ago
InMed Pharmaceuticals Strengthens Patent Portfolio with Issuance of Three U.S. Patents
Compare INM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INM InMed Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.